Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: A pilot study

Bone Marrow Transplantation

Volumn 21, Issue 12, 1998, Pages 1193-1196

  Moreau, P ^a   Milpied, N ^a   Voillat, L ^a   Colombat, P ^a   Mahe B ^a   Rapp, M J ^a   Moreau, A ^a   Dupas, B ^a   Bulabois, C E ^a   Juge Morineau, N ^a   Harousseau, J L ^a  

^a HÔTEL DIEU   (France)

Author keywords

Autologous stem cell transplantation; BEAM regimen; Non Hodgkin's lymphoma

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; AUTOGRAFT; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONDITIONING; FEASIBILITY STUDY; FEMALE; GRANULOCYTE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RELAPSE; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; TIME;

EID: 0031849020     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701272     Document Type: Article

References (20)

1. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New Engl J Med 1987; 316: 1493-1498.
2. Gribben JG, Goldstone AH, Linch DC et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients who are still responsive to conventional-dose therapy. J Clin Oncol 1989; 7: 1621-1629.
3. Philip T, Guglielmi C, Hagenbeek A et al, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
4. Freedman AS, Takvorian T, Neuberg D et al. Autologous bone marrow transplantation in poor prognosis intermediate-grade and high-grade B cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 1993; 11: 931-936.
5. Nademanee A, Schmidt GM, O'Donnell MR et al. High-dose chemotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood 1992; 80: 1130-1134.
6. Verdonck LF, Van Putten WLJ, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. New Engl J Med 1995; 332: 1045-1051.
7. Martelli M, Vignetti M, Zinzani PL et al: High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996; 14: 534-542.
8. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH 87-2. J Clin Oncol 1997; 15: 1131-1137.
9. Pettengel R, Radford JA, Morgenstern GR et al. Survival benefit from high-dose therapy with autologous blood progenitor cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 586-592.
10. Goss PE. Non-Hodgkin's lymphoma in elderly patients. Leuk Lymphoma 1993; 10: 147-156.
11. Shipp MA, Harrington DP, Anderson JR et al. The International non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 987-994.
12. Solal-Céligny P, Chastang C, Herrara A et al. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am J Med 1987; 83: 1075-1080.
13. Vose JM, Armitage JO, Weisenburger DD et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838-1844.
14. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl J Med 1993; 328: 1002-1006.
15. Faucher C, LeCorroler AG, Chabannon C et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996; 17: 533-536.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1979; 53: 457-481.
17. Stamatoullas A, Fruchart C, Khalfallah S et al. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transplant 1997; 19: 31-35.
18. Caballero MD, Rubio V, Rifon J et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451-458.
19. Sweetenham JW, Pearce R, Philip T et al. High-dose therapy and autologous bone marrow transplantation for intermediate and high-grade non-Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14: 981-987.
20. Miller CB, Piantadosi S, Vogelsang GB et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol 1996; 14: 1327-1332.